Valuation: Pulmatrix, Inc.

Market Cap 6.28M 5.49M 5.04M 4.7M 8.91M 598M 9.06M 60.69M 23.52M 293M 23.59M 23.07M 1.01B P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 2.19M 1.92M 1.76M 1.64M 3.11M 209M 3.16M 21.2M 8.21M 102M 8.24M 8.06M 353M EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.26%
Yield 2024 *
-
Yield 2025 -
1 day-1.15%
1 week+2.99%
Current month+1.18%
1 month+30.30%
3 months+31.30%
6 months-23.89%
Current year-22.87%
1 week 1.52
Extreme 1.52
1.75
1 month 1.22
Extreme 1.22
1.75
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
6.96
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
20.8
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 20/07/2024
Director TitleAgeSince
Director/Board Member 58 01/11/2019
Director/Board Member 57 23/06/2020
Director/Board Member 55 01/10/2020
Date Insider Type Main position Quantity % Market Cap.
26/01/23Free

Director

1,700 0.0467%
26/01/23Free

Chief Financial Officer

9,900 0.2720%
26/01/23Free

Director

1,700 0.0467%
Change 5-day change 1-year change 3-year change Capi.($)
-1.15%+2.99%-75.43%-35.82% 6.28M
+3.98%+5.55%+76.40%+132.19% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.13%+12.77%+44.42%-2.20% 18.8B
+4.11%+8.89%+44.60%-27.36% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+4.62%+16.99%+39.95% - 13.9B
Average +2.65%+9.34%+40.36%+125.44% 24.21B
Weighted average by Cap. +2.33%+7.21%+57.08%+135.69%

Financials

2024 2025
Net sales 7.81M 6.82M 6.26M 5.84M 11.07M 743M 11.26M 75.41M 29.23M 364M 29.31M 28.67M 1.26B -
Net income -9.56M -8.35M -7.67M -7.15M -13.56M -910M -13.79M -92.35M -35.79M -446M -35.89M -35.11M -1.54B -5.16M -4.51M -4.14M -3.86M -7.32M -491M -7.45M -49.87M -19.33M -241M -19.38M -18.96M -831M
Net Debt -9.52M -8.32M -7.64M -7.12M -13.51M -906M -13.73M -91.98M -35.65M -445M -35.75M -34.97M -1.53B -4.09M -3.57M -3.28M -3.06M -5.8M -389M -5.9M -39.49M -15.31M -191M -15.35M -15.02M -658M
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
02/07/26 $1.720 -1.15% 34,670
01/07/26 $1.740 +2.35% 17,897
30/06/26 $1.700 +4.29% 15,247
29/06/26 $1.630 -0.61% 25,503
26/06/26 $1.640 -1.80% 27,449
  1. Stock Market
  2. Stocks
  3. PULM Stock